Oral dual-targeted nanosystem for ameliorating colonic barrier injury and secondary liver injury.

Authors

Xi Huang, Ziyi Zhao, Pengyu Ji, Zonghao Guo, Zhi Li

Published in

Nanomedicine : nanotechnology, biology, and medicine. Pages 103033. Oct 02, 2026. Epub Oct 02, 2026.

Abstract

This study designed an oral colon-localized nanomotor system, MS@LA-BBR-(TA/CHI)₅, that achieved passive hepatic accumulation. The system employs aminated mesoporous silica conjugated with L-arginine, loaded with berberine hydrochloride (BBR), and a protective shell constructed via layer-by-layer self-assembly of tannic acid and chitosan. In vitro release studies demonstrated that the nanoformulation exhibited pH-dependent release behavior, and further accelerated drug release in the presence of 3% H₂O₂, confirming the ROS-responsive degradation. Meanwhile, the experimental results of ROS consumption and particle size variation under hydrogen peroxide conditions, further verified the ROS-responsive degradation. In animal experiments, pharmacokinetic results demonstrated that, compared with free BBR, the nanoformulation increased AUC₀-₂₄ h and Cmax by 45.0% and 70.0%, respectively, and shortened the mean absorption time by 30.2%, significantly improving oral bioavailability. In the DSS-induced colitis with liver injury mouse model, the nanomotor system adhered to inflamed colonic sites, penetrated the intestinal barrier, and accumulated in the liver. Notably, FITC-dextran permeability assay confirmed that the nanoformulation effectively restored intestinal barrier function. The results of Oil Red O staining revealed that nanoformulation groups significantly reduced hepatic lipid accumulation, furthermore, serum AST and ALT levels were significantly decreased in the nanoformulation groups compared with the DSS model groups (p < 0.05). Collectively, the nanosystem effectively alleviated colonic barrier injury and hepatic steatosis, offering a promising therapeutic strategy for colitis and secondary liver injury.

PMID:
42826855
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.